MK-8353 - CAS 1184173-73-6
Catalog: |
BB004098 |
Product Name: |
MK-8353 |
CAS: |
1184173-73-6 |
Synonyms: |
(3S)-3-(methylthio)-1-[2-[4-[4-(1-methyl-1,2,4-triazol-3-yl)phenyl]-3,6-dihydro-2H-pyridin-1-yl]-2-oxoethyl]-N-[3-(6-propan-2-yloxy-3-pyridinyl)-1H-indazol-5-yl]-3-pyrrolidinecarboxamide |
Ordering Information
Catalog |
Size |
Price |
Stock |
BB004098 |
50 mg |
$1099 |
In stock |
IUPAC Name: | (3S)-3-methylsulfanyl-1-[2-[4-[4-(1-methyl-1,2,4-triazol-3-yl)phenyl]-3,6-dihydro-2H-pyridin-1-yl]-2-oxoethyl]-N-[3-(6-propan-2-yloxypyridin-3-yl)-1H-indazol-5-yl]pyrrolidine-3-carboxamide |
Description: | MK-8353 is an orally available ERK1/2 inhibitor. It exhibited antitumor activity in patients with BRAFV600-mutant melanoma. |
Molecular Weight: | 691.84 |
Molecular Formula: | C37H41N9O3S |
Canonical SMILES: | CC(C)OC1=NC=C(C=C1)C2=NNC3=C2C=C(C=C3)NC(=O)C4(CCN(C4)CC(=O)N5CCC(=CC5)C6=CC=C(C=C6)C7=NN(C=N7)C)SC |
InChI: | InChI=1S/C37H41N9O3S/c1-24(2)49-32-12-9-28(20-38-32)34-30-19-29(10-11-31(30)41-42-34)40-36(48)37(50-4)15-18-45(22-37)21-33(47)46-16-13-26(14-17-46)25-5-7-27(8-6-25)35-39-23-44(3)43-35/h5-13,19-20,23-24H,14-18,21-22H2,1-4H3,(H,40,48)(H,41,42)/t37-/m0/s1 |
InChI Key: | KPQQGHGDBBJGFA-QNGWXLTQSA-N |
LogP: | 5.21830 |
Publication Number | Title | Priority Date |
WO-2021127043-A1 | Combinations | 20191220 |
WO-2021079302-A1 | Pharmaceutical combination of prmt5 inhibitors | 20191022 |
WO-2021007499-A1 | Combination therapies for managing cancer | 20190711 |
US-2018250232-A1 | Process for preparing spray dried solid dispersions of (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide for pharmaceutical preparations | 20150903 |
WO-2017040362-A1 | Process for preparing spray dried solid dispersions of (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3- (methylthio)pyrrolidine-3-carboxamide for pharmaceutical preparations | 20150903 |
PMID | Publication Date | Title | Journal |
29467321 | 20180222 | Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors | JCI insight |
5086 | 19760405 | On the autoxidation of bilirubin | Biochemical and biophysical research communications |
Complexity: | 1220 |
Compound Is Canonicalized: | Yes |
Covalently-Bonded Unit Count: | 1 |
Defined Atom Stereocenter Count: | 1 |
Defined Bond Stereocenter Count: | 0 |
Exact Mass: | 691.30530738 |
Formal Charge: | 0 |
Heavy Atom Count: | 50 |
Hydrogen Bond Acceptor Count: | 9 |
Hydrogen Bond Donor Count: | 2 |
Isotope Atom Count: | 0 |
Monoisotopic Mass: | 691.30530738 |
Rotatable Bond Count: | 10 |
Topological Polar Surface Area: | 160 |
Undefined Atom Stereocenter Count: | 0 |
Undefined Bond Stereocenter Count: | 0 |
XLogP3: | 4.3 |
Online Inquiry
Customer Support
Customer Centered
Related Functional Groups
Carbonyl Compounds
Customers Also Viewed
-
[76799-38-7]
1-[4-Hydroxy-2,6-bis(phenylmethoxy)phenyl]ethanone
-
[31295-54-2]
1,4-Piperazinediethanamine, N-(2-aminoethyl)-
-
[1179-06-2]
1,4-Bis(diphenylphosphino)benzene
-
[223259-63-0]
(S)-SPINOL
-
[20324-32-7]
1-(2-Methoxy-1-methylethoxy)propan-2-ol
-
[51072-36-7]
1-(4-Methoxybenzyl)-1,2,3,4,5,6,7,8-octahydroisoquinoline
INDUSTRY LEADERS TRUST OUR PRODUCTS